The medication-assisted treatment (MAT) market is experiencing significant growth due to its effectiveness in treating substance use disorders, particularly opioid addiction. MAT combines medications, counseling, and behavioral therapies to provide a comprehensive approach to patient recovery. The market is driven by the need for improved patient outcomes, including increased treatment retention, reduced illicit drug use, and improved pregnancy outcomes. With the rising demand for MAT, the market is expected to expand further in the coming years.
Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/global-medication-assisted-treatment-mat-market
The Global Medication-Assisted Treatment (MAT) Market is expected to reach USD 16,808.38 million by 2029 from USD 8191.94 million in 2021 with a CAGR of 9.4% in the forecast period of 2022 to 2029. The increasing prevalence of substance use disorders, particularly opioid addiction, is driving the demand for effective treatment options like medication-assisted treatment (MAT). This growing need for evidence-based and comprehensive treatment approaches is a significant driver of the MAT treatment market.
Key Findings of the Study
Advancements in medications designed for Medication-Assisted Treatment are expected to drive the market's growth rate
Advancements in medications designed for medication-assisted treatment (MAT), such as buprenorphine-naloxone (Suboxone) and extended-release naltrexone (Vivitrol), are significant drivers of the MAT treatment market. These new medications and formulations have expanded the treatment options available to healthcare providers and patients, improving patient outcomes and medication adherence. The development of more effective and convenient MAT medications is driving market growth by addressing the specific needs and challenges of individuals seeking substance use disorder treatment, thus increasing the adoption and utilization of MAT.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals Specialty Centres, Homecare and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Norway, Poland, Hungary, Lithuania, Austria, Ireland, and Rest of Europe., China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific, Brazil, Argentina, Peru and Rest of South America. South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, and the Rest of Middle East and Africa.
|
|
Market Players Covered
|
Indivior PLC (U.K.), Orexo US Inc (a subsidiary of Orexo AB) (U.S.), Recovery Centers of America (U.S.), Alkermes (Ireland), Sun Pharmaceutical Industries Ltd. (India), Purdue Pharma L.P. (U.S.), Taj Pharmaceuticals Limited (India) Lannett (U.S.), Hikma Pharmaceuticals PLC (Jordan), Pfizer Inc. (U.S.), Pinnacle Treatment Center (U.S.), American Addiction Centers (U.S.) Adamis Pharmaceuticals Corporation (U.S.), Glenmark Pharmaceutical Inc. (U.S.), Viatris Inc. (U.S.) Mallinckrodt (U.K.) Alvogen (Taiwan) Accord Healthcare (U.K.) VistaPharm, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel) Dr. Reddy's Laboratories Ltd. (India) Amneal Pharmaceuticals LLC (U.S.) Titan Pharmaceuticals, Inc. (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The medication-assisted (MAT) treatment market is segmented on the basis of eight segments type, products, drug type, dosage form, route of administration, population type, end user, and distribution channel.
- On the basis of type, the medication-assisted (MAT) treatment market is segmented into medication and therapy. The medication segment dominates the type segment in the medication-assisted (MAT) treatment market with a CAGR of 9.9% due to its effectiveness in managing substance use disorders. Medications such as methadone, buprenorphine, and naltrexone are widely prescribed to reduce withdrawal symptoms, cravings, and the risk of relapse in the forecast period of 2022 to 2029
In 2022 the medication segment type segment is dominating the medication-assisted (MAT) treatment market
In 2022 the medication segment of type segment is dominating the medication-assisted (MAT) treatment market with a CAGR of 9.9% due to its effectiveness in managing substance use disorders. Medications such as methadone, buprenorphine, and naltrexone are widely utilized in MAT programs to reduce withdrawal symptoms, cravings, and illicit drug use. These medications, combined with counseling and behavioral therapies, provide comprehensive treatment options for individuals struggling with opioid addiction. The medication segment's dominance is attributed to its evidence-based approach, long-term outcomes, and endorsement by regulatory bodies and healthcare providers in the forecast period of 2022 to 2029.
- On the basis of products, the medication-assisted (MAT) treatment market is segmented into buprenorphine and naloxone, naltrexone, buprenorphine, methadone, naloxone, disulfiram and acamprosate. The buprenorphine and naloxone segment dominates the products segment with a CAGR of 11% due to its effectiveness in managing opioid addiction. Buprenorphine helps reduce cravings and withdrawal symptoms, while naloxone blocks the effects of opioids and prevents misuse during the forecast period of 2022-2029.
- On the basis of drug type, the medication-assisted (MAT) treatment market is segmented into generics and branded. The generics segment dominates the drug type segment with a CAGR of 10.2% due to cost-effectiveness and widespread availability. Generic medications, which are bioequivalent to brand-name drugs, offer similar efficacy at lower prices during the forecast period of 2022-2029.
- On the basis of dosage form, the medication-assisted (MAT) treatment market is segmented into immediate release and extended release. The immediate release segment dominates the dosage form with a CAGR of 10.2% due to the quick onset of action and flexibility in dosing. Immediate-release formulations provide rapid relief of withdrawal symptoms and cravings, making them an effective choice for managing substance use disorders during the forecast period of 2022-2029.
- On the basis of route of administration, the medication-assisted (MAT) treatment market is segmented into oral, parenteral and others. The oral segment dominates the route of administration segment in the medication-assisted (MAT) treatment market with the CAGR of 10.4% due to its convenience, patient acceptance, and ease of administration. Oral medications are administered by mouth, making them a non-invasive and user-friendly option during the forecast period of 2022-2029.
- On the basis of population type, the medication-assisted (MAT) treatment market is segmented into adults and teenage. The adults segment dominates the population type with the CAGR of 9.5% due to higher prevalence of substance use disorders in this demographic. MAT primarily targets adults struggling with addiction, offering medications to reduce cravings, withdrawal symptoms, and the risk of relapse during the forecast period of 2022-2029.
- On the basis of end user, the medication-assisted (MAT) treatment market is segmented into rehabilitation clinics, hospitals specialty centres, homecare, and others. The rehabilitation clinics dominate the end user segment in the medication-assisted (MAT) treatment market with a CAGR of 10.4% due to their specialized focus on addiction treatment. Rehabilitation clinics offer comprehensive care and support for individuals seeking recovery from substance use disorders. They provide a structured environment, experienced healthcare professionals, and tailored MAT programs during the forecast period of 2022-2029.
- On the basis of distribution channel, the medication-assisted (MAT) treatment market is segmented into hospital pharmacy, direct tender, retail pharmacy, online pharmacy and others. The hospital pharmacy segment dominates the distribution channel with the CAGR 10.5% due to its integral role in providing medications for MAT interventions. Hospital pharmacies have direct access to a wide range of medications and are equipped to prepare and dispense them to patients during the forecast period of 2022-2029.
IN 2022, the hospital pharmacy segment dominates the distribution channel segment in medication-assisted (MAT) treatment market
IN 2022, the hospital pharmacy segment dominates the distribution channel segment in medication-assisted (MAT) treatment market with a CAGR of 10.5% due to several reasons such as, hospitals being equipped with specialized pharmacy services and experienced healthcare professionals who are well-versed in MAT protocols. They have the knowledge and expertise to provide comprehensive treatment and ensure the safe and effective delivery of medications. Additionally, hospital pharmacies offer a wide range of medications used in MAT, allowing for personalized treatment plans tailored to individual patient needs in the forecast period of 2022 to 2029.
Major Players
Data Bridge Market Research recognizes the following companies as the major global medication-assisted treatment (Mat) market players in Global medication-assisted treatment (Mat) market are Sun Pharmaceutical Industries Ltd. (India), Purdue Pharma L.P. (U.S.), Taj Pharmaceuticals Limited (India) Lannett (U.S.), Hikma Pharmaceuticals PLC (Jordan), Pfizer Inc. (U.S.), Pinnacle Treatment Center (U.S.)
Market Development
- In April 2021, Adamis Pharmaceuticals Corporation, in collaboration with USWM, introduced a high-dose ZIMHI injectable naloxone product to combat opioid overdose deaths. The launch is anticipated to drive revenue in the product segment, fostering market growth.
- In February 2021, the American College of Emergency Physicians (ACEP) introduced the Reimbursement & Coding FAQs and Pearls as a resource for information on medication-assisted treatment (MAT). This initiative aimed to provide valuable guidance on the reimbursement and coding aspects of MAT, helping healthcare providers navigate the complexities and ensure proper documentation and billing for MAT services
Regional Analysis
Geographically, the countries covered in the Global medication-assisted treatment (Mat) market report are U.S., Canada and Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Norway, Poland, Hungary, Lithuania, Austria, Ireland, and Rest of Europe., China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific, Brazil, Argentina, Peru and Rest of South America. South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, and the Rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is projected to dominant region in the global medication-assisted treatment (MAT) market during the forecast period 2022-2029
North America is projected to dominate the medication-assisted treatment (MAT) market due to several factors. Such as, the region has witnessed a significant increase in the incidence of substance use disorders, particularly opioid addiction, driving the demand for effective treatment options like MAT. Additionally, ongoing clinical trials in North America contribute to advancements in MAT medications and treatment approaches. Furthermore, the presence of major pharmaceutical companies in the region supports the development, production, and distribution of MAT products, further bolstering North America's market dominance in the MAT field.
For more detailed information about the Global medication-assisted treatment (MAT) market report, click here – https://www.databridgemarketresearch.com/fr/reports/global-medication-assisted-treatment-mat-market
